This two-part study will evaluate the effect of golimumab in participants with active axial spondyloarthritis. In Part 1, participants will receive golimumab 50 mg or matching placebo subcutaneous injections on Day 1 (Baseline) and at Weeks 4, 8, and 12. During Part 1 of the study participants will not know the identity of the injection. In the Part 2 extension all participants receive golimumab 50 mg subcutaneous injections beginning on Week 16 and then every 4 weeks up to Week 48. In Part 2 the participants will be told they are receiving active study drug.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01453725?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
